| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 04/04/2002 | CA2423434A1 Lactone integrin antagonists |
| 04/04/2002 | CA2423313A1 Methods of treating inflammatory and immune reactions and compositions therefor |
| 04/04/2002 | CA2423251A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| 04/04/2002 | CA2421851A1 Tgf-.beta. inhibitors and methods |
| 04/04/2002 | CA2421209A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein junkinases |
| 04/04/2002 | CA2420672A1 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 04/04/2002 | CA2420577A1 Peptide-based compounds |
| 04/04/2002 | CA2420475A1 Ige receptor antagonists |
| 04/04/2002 | CA2420045A1 Melanocortin receptor ligands |
| 04/04/2002 | CA2416656A1 Compositions and methods for the endocytic presentation of immunosuppressive factors |
| 04/03/2002 | EP1193268A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases |
| 04/03/2002 | EP1193267A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases |
| 04/03/2002 | EP1193261A1 New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| 04/03/2002 | EP1192945A2 Use of an estrogen agonist/antagonist for treating osteoarthritis |
| 04/03/2002 | EP1192278A1 48 human secreted proteins |
| 04/03/2002 | EP1192261A1 22025, a novel human cyclic nucleotide phosphodiesterase |
| 04/03/2002 | EP1192258A2 Human poly(adp-ribose) polymerase 2 materials and methods |
| 04/03/2002 | EP1192257A2 Human regulators of intracellular phosphorylation |
| 04/03/2002 | EP1192250A2 Human rna metabolism proteins (rmep) |
| 04/03/2002 | EP1192174A2 Antagonists of bmp and tgf beta signalling pathways |
| 04/03/2002 | EP1192171A1 48 human secreted proteins |
| 04/03/2002 | EP1192151A1 Anilinoquinazolines as protein tyrosine kinase inhibitors |
| 04/03/2002 | EP1192137A1 COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY |
| 04/03/2002 | EP1192133A1 N-cyclopentyl modulators of chemokine receptor activity |
| 04/03/2002 | EP1192132A2 Serine protease inhibitors |
| 04/03/2002 | EP1191945A1 Methods and compositions for control of bone formation via modulation of leptin activity |
| 04/03/2002 | EP1191940A1 Tumor necrosis factor receptor 5 |
| 04/03/2002 | EP1191934A1 Il-8 receptor antagonists |
| 04/03/2002 | EP1191931A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 |
| 04/03/2002 | EP1007512B1 Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors |
| 04/03/2002 | EP0986574B1 11beta-aryl substituted 14,17-ethano-oestratriens, method for the production of these compounds and their use in the production of medicaments. |
| 04/03/2002 | EP0931087B1 Novel pyranoside derivatives |
| 04/03/2002 | EP0809512B1 Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin |
| 04/03/2002 | EP0775199B1 Superoxide dismutase-4 |
| 04/03/2002 | CN1343213A 2,3-0-isopropylidene derivatives of monosaccharides as cell adhesive inhibitors |
| 04/03/2002 | CN1343206A Cyclocompound |
| 04/03/2002 | CN1343122A Remedies for joint diseases |
| 04/03/2002 | CN1342653A 1,6-fructostrontium biphosphate compounds and their preparing process and medical application |
| 04/03/2002 | CN1342488A Chinese medicine preparation 'Jiangudan' |
| 04/03/2002 | CN1342485A Exterior-applied medical wine for treating trauma |
| 04/03/2002 | CN1342468A Capsule for treating rheumatic and rheumatoid arthritis and its preparing process |
| 04/03/2002 | CN1081930C Medicine powder for treating bone bi-syndrome and its preparation method |
| 04/03/2002 | CN1081923C Chitosan and use of polysaccharide fixed on it in producing hard tissue irritant |
| 04/02/2002 | US6365749 Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| 04/02/2002 | US6365736 Benzoxazine and benzothiazine derivatives and their use in pharmaceuticals |
| 04/02/2002 | US6365600 For therapy of condition associated with smooth muscle cell proliferation in a warm-blooded animal which comprises administering imidazol-5-yl-methyl-2-quinolinone derivatives |
| 04/02/2002 | US6365587 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 04/02/2002 | US6365572 For therapy of diseases related to increased or unwanted synthesis of basement membranes such as diabetes mellitus; atherosclerosis; cancer; diabetic retinopathia; fibroplasia retrolentalis; or psoriasis, rheumatoic arthritis |
| 04/02/2002 | US6365405 Compositions of chondrocytes, preparation and utilization |
| 04/02/2002 | US6365389 Human protein kinase H2LAU20 |
| 04/02/2002 | US6364912 Pleiotrophin-based compositions for enhancing connective tissue repair |
| 04/02/2002 | CA2357925A1 Prophylactic use of n-methyl-d-asparate (nmda) antagonists |
| 03/29/2002 | WO2003045398A1 Methods of making and pharmaceutical formulations comprising 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof |
| 03/28/2002 | WO2002024943A2 Method of identifying osteoregenerative agents using differential gene expression |
| 03/28/2002 | WO2002024924A2 Protein phosphatases |
| 03/28/2002 | WO2002024923A1 Polypeptide having phospholipase a2 actiivty |
| 03/28/2002 | WO2002024909A2 Receptor nucleic acids and polypeptides |
| 03/28/2002 | WO2002024891A2 B7-like molecules and uses thereof |
| 03/28/2002 | WO2002024727A2 New inhibitors of iapp fibril formation and uses thereof |
| 03/28/2002 | WO2002024711A1 Novel thiazole bicyclic compounds |
| 03/28/2002 | WO2002024706A2 Water soluble rapamycin esters |
| 03/28/2002 | WO2002024702A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | WO2002024697A1 Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient |
| 03/28/2002 | WO2002024693A1 A process for producing 3,4-dihydro naphthyridinone analogs |
| 03/28/2002 | WO2002024683A1 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives |
| 03/28/2002 | WO2002024681A2 Pyrazine derivatives as modulators of tyrosine kinases |
| 03/28/2002 | WO2002024679A1 PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY |
| 03/28/2002 | WO2002024674A1 Benzoic acid derivatives and uses thereof |
| 03/28/2002 | WO2002024653A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | WO2002024651A1 A process for producing 2-amino-4,6-disubstituted nicotinic acid ester analogs |
| 03/28/2002 | WO2002024639A1 Cyclopentane derivatives as therapeutic agents |
| 03/28/2002 | WO2002024307A2 Reducing the content of particular cell types in a biological sample |
| 03/28/2002 | WO2002024229A1 Method of regulating osteoclast formation |
| 03/28/2002 | WO2002024228A1 Method of regulating osteoclast formation |
| 03/28/2002 | WO2002024222A2 Ligands for g protein coupled receptors and methods of using them |
| 03/28/2002 | WO2002024219A1 Growth factor complex |
| 03/28/2002 | WO2002024218A1 Angiogenic agents and their uses |
| 03/28/2002 | WO2002024214A2 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 03/28/2002 | WO2002024206A1 Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
| 03/28/2002 | WO2002024190A1 Use of r-arylpropionic acids for producing medicaments for treating illnesses with a rheumatic nature |
| 03/28/2002 | WO2002024162A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
| 03/28/2002 | WO2001096336A3 6,5-fused bicyclic heterocycles |
| 03/28/2002 | WO2001083434A3 P-(sulfonyl)-aryl and heteroaryls amines |
| 03/28/2002 | WO2001077075A3 Inhibitors of inflammation and reperfusion injury |
| 03/28/2002 | WO2001070977A3 Fibroblast growth factor receptor-like molecules and uses thereof |
| 03/28/2002 | WO2001066107A3 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 03/28/2002 | WO2001062793A3 Estrogen receptor beta variants and methods of detection thereof |
| 03/28/2002 | WO2001055357A3 Myeloid colony stimulating factor and uses thereof |
| 03/28/2002 | WO2001052825A3 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 03/28/2002 | WO2001051032A3 Micronized freeze-dried particles |
| 03/28/2002 | WO2001043756A3 Regenerative adjuvant |
| 03/28/2002 | WO2001035936A3 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases |
| 03/28/2002 | WO2001032216A3 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 03/28/2002 | WO2001007405A3 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 03/28/2002 | WO2000066102A3 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| 03/28/2002 | WO2000063241A9 Methods and compositions for modulating an immune response |
| 03/28/2002 | WO2000047231A9 Novel antisense inhibition of rad51 |
| 03/28/2002 | US20020038469 Delayed progression to aids by a missense allele of the ccr2 gene |
| 03/28/2002 | US20020038002 To suppress immune system for therapy of symptoms associated with immune disorders such as allergies, transplanted tissue rejection and autoimmune diabetes, rheumatoid arthritis and multiple sclerosis |
| 03/28/2002 | US20020037927 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |